Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) fell 7.1% during trading on Wednesday . The stock traded as low as $2.99 and last traded at $3.02. 645,888 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 2,273,840 shares. The stock had previously closed at $3.25.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen downgraded shares of Liminatus Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 2nd.
Read Our Latest Report on Liminatus Pharma
Liminatus Pharma Stock Performance
Liminatus Pharma Company Profile
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Featured Articles
- Five stocks we like better than Liminatus Pharma
- What is a Special Dividend?
- Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to Do
- Using the MarketBeat Dividend Yield Calculator
- 3 Undervalued Stocks Analysts Are Loving Right Now—Should You?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
